SecBot SecBot
6-K ·Filed Apr 23, 2026

DRTSW

Alpha Tau Medical Ltd.
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago SEC0001213900-26-046897
Notable filing: 6-K
Actionable Insight ▲ Bullish

Monitor upcoming clinical data readouts from both ACAPELLA and IMPACT trials, particularly tumor response and resectability rates, which could serve as key value inflection points. Increased trial size and geographic expansion improve data robustness and potential for future regulatory submissions.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.02
T+0 close · Apr 23, 2026 · via day close
Latest settled
+268.63%
T+60 · $3.76
Vs SPY
+263.61%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 23 $1.02entry
  2. T+1 · 7mo ago 0.00%α −0.78% · $1.02
  3. T+5 · 7mo ago 0.00%α −1.48% · $1.02
  4. T+20 · 6mo ago 0.00%α −4.63% · $1.02
  5. T+60 · 4mo ago +268.63%α +263.61% · $3.76

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau Medical announced two clinical trial advancements: the first patient treated in Europe under the ACAPELLA trial for pancreatic cancer and FDA approval to expand its U.S.-based IMPACT trial to include patients on gemcitabine/nab-paclitaxel chemotherapy, increasing total enrollment to 40 patients. These developments mark progress in the company's global clinical strategy for its Alpha DaRT therapy.

Key Facts

  • First patient treated in Europe under the ACAPELLA trial for inoperable locally advanced pancreatic cancer (LAPC) at CHU Grenoble Alpes.
  • FDA approved an IDE supplement to expand the IMPACT trial in the U.S., Canada, and Israel to include patients receiving gemcitabine/nab-paclitaxel, increasing total enrollment from 30 to 40 patients.
  • ACAPELLA trial evaluates Alpha DaRT combined with capecitabine in patients who completed mFOLFIRINOX; IMPACT trial evaluates Alpha DaRT with standard chemotherapy in newly diagnosed unresectable or metastatic pancreatic adenocarcinoma.
  • Both trials are multicenter and aim to assess safety, feasibility, tumor response, and potential conversion to surgical resectability.

Financial Impact

No direct financial impact disclosed; trial expansions represent de-risking of clinical development path.

R&D pipeline progressregulatory milestonesclinical trial enrollment

Risk Factors

  • Clinical trial results may not meet endpoints or demonstrate sufficient efficacy.
  • Regulatory delays or requirements for additional data could impact development timeline.
  • Company remains pre-revenue with significant losses and dependence on future funding.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-046897
Document: ea028745101ex99-2.htm0001213900-26-046897
Document: ea0287451-6k_alphatau.htm0001213900-26-046897
Document: 0001213900-26-046897-index-headers.html0001213900-26-046897
Document: 0001213900-26-046897-index.html0001213900-26-046897
Document: 0001213900-26-046897.txt0001213900-26-046897

US Market Status

Market Closed · Opens in 7h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026